Real-world outcomes of tafasitamab-lenalidomide in patients with transplant-ineligible R/R DLBCL from the PRO-MIND study
Authors:
- Pier Luigi ZinzaniPZPier Luigi Zinzani
- Maria Cristina CoxMCMaria Cristina Cox
- Flaminia BellisarioFBFlaminia Bellisario
- Andrea BernardelliABAndrea Bernardelli
- Maurizio MussoMMMaurizio Musso
- Guido GiniGGGuido Gini
- Alice Di RoccoARAlice Di Rocco
- Eliana Valentina LiardoELEliana Valentina Liardo
- Enrico DerenziniEDEnrico Derenzini
- Elsa PenneseEPElsa Pennese
- Nicola BattagliaNBNicola Battaglia
- Mario LapecorellaMLMario Lapecorella
Open Access
- 14 May 2026
- journal article
- Published by Elsevier in Blood Immunology & Cellular Therapy
- Vol. 2 (3)
Abstract
No abstract availableFunding Information
- Incyte
- Envision
This publication has 7 references indexed in Scilit:
- Tafasitamab plus lenalidomide as salvage therapy in diffuse large B-cell lymphoma: real-world experience from GELTAMOBlood Advances, 2025
- Real-World Effectiveness of Chemoimmunotherapy and Novel Therapies for Patients With Relapsed/Refractory Aggressive Large B-Cell LymphomaClinical Lymphoma Myeloma and Leukemia, 2024
- Real-world outcomes with novel therapies in relapsed/refractory diffuse large B-cell lymphomaLeukemia & Lymphoma, 2024
- Tafasitamab and lenalidomide in large B-cell lymphoma: real-world outcomes in a multicenter retrospective studyBlood, 2023
- Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 studyThe Lancet Oncology, 2020
- Diffuse large B‐cell lymphoma with primary treatment failure: Ultra‐high risk features and benchmarking for experimental therapiesAmerican Journal of Hematology, 2016
- Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano ClassificationJournal of Clinical Oncology, 2014